Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus
04 nov. 2021 04h00 HE
|
Vaccitech (UK) Limited
The Phase 1 clinical trial was conducted by The King Abdullah International Medical Research Centre (KAIMRC), in the Kingdom of Saudi Arabia (KSA), in partnership with the University of Oxford....
Vaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021
18 oct. 2021 08h00 HE
|
Vaccitech (UK) Limited
OXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...
Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe
13 oct. 2021 08h00 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech to Present at Upcoming September Investor conferences
09 sept. 2021 08h00 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
12 août 2021 08h00 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of...
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
08 juil. 2021 08h00 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, July 08, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments
14 juin 2021 17h49 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech to Present at the Jefferies Virtual Healthcare Conference
01 juin 2021 08h00 HE
|
Vaccitech Limited
OXFORD, United Kingdom, June 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Announces Closing of $110.5 Million Initial Public Offering
04 mai 2021 17h07 HE
|
Vaccitech Limited
OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech Announces Pricing of Initial Public Offering
29 avr. 2021 18h49 HE
|
Vaccitech Limited
OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...